Ventyx Biosciences

Historical price data

Ventyx Biosciences leverages expertise in medicinal chemistry, structural biology, and immunology to discover and develop differentiated oral therapeutics for diseases with high unmet need. Its clinical-stage pipeline is built around two core platforms: NLRP3 inflammasome inhibitors (with both peripheral and CNS-penetrant candidates) and immunomodulators for inflammatory bowel disease (S1P1R and TYK2). The company's strategic acquisition by Lilly in early 2026 validates its platform and provides significant resources to advance its programs.

The company's core platform is focused on the discovery and development of oral small molecule inhibitors of the NLRP3 inflammasome, a master regulator of inflammation, with programs split into peripherally-restricted and CNS-penetrant candidates.

3 drugs in pipeline

Total raised: $368M

Ventyx competes in the NLRP3 inhibitor space with companies like NodThera and Ventus Therapeutics, and in IBD with approved S1P1R and TYK2 modulators from major pharma. Its primary differentiation is the advanced clinical stage of its dual (peripheral/CNS) NLRP3 pipeline and, post-acquisition, the strategic and financial backing of Eli Lilly.